Skip to content
PeptideAgent

Peptides for insulin resistance and prediabetes: what the evidence shows

By the PeptideAgent Editorial Team. Draft, pending editorial review.  Last verified

At a glance

Lifestyle change is the best proven intervention: in the Diabetes Prevention Program, intensive lifestyle change cut progression to type 2 diabetes by 58% and metformin by 31%. Among peptides, liraglutide 3.0 mg reduced prediabetes in a large trial, NMN and carnosine have small human trials on insulin sensitivity, and MOTS-c and humanin data come from rodents.

Evidence: Strongest: Human RCT evidence5 peptides gradedVerified: Verified Sep 27, 2026

Do peptides help with insulin resistance and prediabetes?

5 peptides are graded for insulin resistance and prediabetes on this page. The strongest grade is human RCT evidence, for liraglutide, NAD+, and carnosine. Each one is weighed against the standard of care below, and the evidence table gives the grade and a note for every peptide.

What is the standard of care for insulin resistance and prediabetes?

A structured lifestyle program targeting about 7% weight loss and 150 minutes of weekly activity; metformin for higher risk prediabetes (for example BMI 35 or higher, age under 60, or prior gestational diabetes); treat blood pressure and lipids; recheck glucose at least yearly.

Any peptide below should be judged against this baseline, not against doing nothing. Talk to a licensed provider before replacing or adding to an established treatment.

Which peptides have been studied for insulin resistance and prediabetes?

Ordered by strength of evidence for this use. Grades follow the methodology; each peptide page lists the individual studies.

Peptides studied for Insulin resistance and prediabetes with evidence grades
PeptideEvidence for this useNote
LiraglutideEvidence: Human RCT evidenceIn SCALE Obesity and Prediabetes (n = 3,731), liraglutide 3.0 mg with lifestyle counseling lowered the share of participants with prediabetes and improved insulin sensitivity measures over 56 weeks. [2] [6]
NAD+Evidence: Human RCT evidenceOral NMN 250 mg daily improved muscle insulin sensitivity by about 25% in 25 prediabetic women over 10 weeks; injectable NAD+ has not been tested for this. [3]
CarnosineEvidence: Human RCT evidenceA 30 person pilot trial found carnosine 2 g daily prevented the rise in fasting insulin and insulin resistance seen on placebo; not a regulated drug. [4]
MOTS-cEvidence: Animal-only evidencePrevented diet induced insulin resistance in mice; human genetic association data do not raise the grade. [5]
HumaninEvidence: Animal-only evidenceImproved hepatic insulin sensitivity in rats through a brain signaling pathway; no human dosing studies. [7]

Head-to-head comparisons

Cost and access

Price ranges, lawful channels, and insurance notes for peptides graded here. State rules are in the legal guides by state.

Frequently asked questions

Which peptide has the strongest evidence for insulin resistance and prediabetes?

Liraglutide, NAD+, and carnosine have the strongest evidence among the peptides graded here, at human RCT evidence. Liraglutide: In SCALE Obesity and Prediabetes (n = 3,731), liraglutide 3.0 mg with lifestyle counseling lowered the share of participants with prediabetes and improved insulin sensitivity measures over 56 weeks. NAD+: Oral NMN 250 mg daily improved muscle insulin sensitivity by about 25% in 25 prediabetic women over 10 weeks; injectable NAD+ has not been tested for this. Carnosine: A 30 person pilot trial found carnosine 2 g daily prevented the rise in fasting insulin and insulin resistance seen on placebo; not a regulated drug. [2] [3] [4] [6]

Is any peptide FDA approved for insulin resistance and prediabetes?

Liraglutide is an FDA approved drug, but an approval covers only the indications on that label, so check the label before assuming it applies to insulin resistance and prediabetes. The other peptides graded here are not FDA approved. [2] [6] [8]

Has any peptide been tested in a randomized trial for insulin resistance and prediabetes?

Yes, for liraglutide, NAD+, and carnosine. Check each note for the population and endpoints: a randomized trial in a related group or on a surrogate marker is weaker than one on the outcome you care about. [2] [3] [4] [6]

From the blog

Sources

  1. [1]Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002 (Diabetes Prevention Program)PubMed 11832527, 2002
  2. [2]A randomized, controlled trial of 3.0 mg of liraglutide in weight management (SCALE Obesity and Prediabetes)PubMed 26132939, 2015
  3. [3]Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic womenPubMed 33888596, 2021
  4. [4]Effects of carnosine supplementation on glucose metabolism: pilot clinical trialPubMed 27040154, 2016
  5. [5]The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance (Cell Metab 2015)PubMed 25738459, 2015
  6. [6]FDA prescribing information for Saxenda (liraglutide) injection, via DailyMedFDA, 2025
  7. [7]A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and AbetaPubMed 11371646, 2001
  8. [8]Drugs@FDA: FDA-approved drugs databaseFDA